Table 1.
Characteristics of patients with persistent GP versus complete remission
| Characteristic | Persistent disease (N = 59) | Complete remission (N = 61) | OR | CI 95% | p Value |
|---|---|---|---|---|---|
| Follow-up, years, mean (SD) | 6.5 (3.3) | 5.7 (2.9) | 1.09 | 0.97–1.22 | 0.08 |
| Age at first event, years, mean (SD) | 27.9 (14.3) | 29.3 (16.3) | 0.99 | 0.97–1.01 | 0.44 |
| Female gender (%) | 29 (49.2) | 41 (67.2) | 0.47 | 0.22–0.98 | 0.04 |
| Family history of psoriasis | 25 (42.2) | 18 (30.0) | 1.71 | 0.80–3.65 | 0.16 |
| Missing data | n = 1 | n = 1 | |||
| Episodes, n (%) | |||||
| 1 | 7 (11.9) | 42 (68.9) | 0.06 | 0.02–0.15 | 0.001 |
| 2–3 | 20 (33.3) | 12 (19.6) | 2.09 | 0.91–4.80 | 0.07 |
| Over 3 | 32 (54.2) | 7 (11.5) | 9.14 | 3.57–23.38 | 0.001 |
| Area involved | |||||
| Trunk | 50 (90.9) | 54 (94.7) | 0.55 | 0.12–2.44 | 0.43 |
| Limbs | 52 (94.5) | 55 (96.5) | 0.63 | 0.10–3.92 | 0.61 |
| Head | 24 (43.6) | 28 (49.1) | 0.80 | 0.38–1.68 | 0.56 |
| Diffuse | 23 (41.8) | 27 (47.4) | 0.79 | 0.37–1.68 | 0.55 |
| Missing data | N = 4 | N = 4 | |||
| URTI anticipating GP flare | |||||
| At first GP episode | 37 (62.7) | 39 (63.9) | 0.94 | 0.45–1.99 | 0.88 |
| At some GP episodes | 41 (67.2) | 41 (69.2) | 1.11 | 0.51–2.40 | 0.78 |
| With confirmed streptococcal infection a | 13 (65.0) | 10 (40.0) | 2.78 | 0.82–9.42 | 0.95 |
| Missing data | N = 39 | N = 36 | |||
| Hand and foot involvement | |||||
| At first GP episode | 15 (30.0) | 5 (12.2) | 3.08 | 1.03–9.40 | 0.04 |
| At some GP episodes | 21 (42.0) | 5 (12.2) | 5.21 | 1.75–15.52 | 0.002 |
| Missing data | N = 18 | N = 11 | |||
| Scalp involvement | |||||
| At first episode | 30 (50.8) | 26 (43.3) | 1.35 | 0.65–2.78 | 0.41 |
| At some GP episodes | 38 (64.4) | 28 (46.7) | 2.06 | 0.99–4.31 | 0.05 |
| Missing data | N = 0 | N = 1 | |||
| Comorbidity, n (%) | |||||
| Arthritis | 12 (20.3) | 6 (9.8) | 2.34 | 0.81–6.71 | 0.10 |
| Hypertension | 5 (8.5) | 3 (4.9) | 1.79 | 0.40–7.85 | 0.43 |
| Hyperlipidemia | 6 (10.2) | 3 (4.9) | 2.18 | 0.52–9.19 | 0.27 |
| Diabetes | 4 (6.8) | 1 (1.6) | 4.36 | 0.47–40.24 | 0.15 |
| Obesity | 5 (8.5) | 6 (9.8) | 0.84 | 0.24–2.94 | 0.79 |
| Disease state | |||||
| Transformed to vulgaris phenotype | 16 (27.1) | 5 (8.2) | 4.16 | 1.41–12.27 | 0.006 |
| Most potent treatment at first GP episode | |||||
| Topical | 4 (7.0) | 10 (16.9) | 0.37 | 0.10–1.25 | 0.10 |
| Phototherapy | 48 (84.2) | 46 (78.0) | 1.50 | 0.58–3.86 | 0.39 |
| Oral agentsb | 5 (8.8) | 3 (5.1) | 1.79 | 0.40–7.88 | 0.43 |
| Biological | 0 (0) | 0 (0) | |||
| Missing data | N = 2 | N = 2 | |||
| Most potent treatment along disease course | |||||
| Topical | 5 (8.5) | 10 (16.4) | 0.47 | 0.15–1.47 | 0.19 |
| Phototherapy | 42 (71.2) | 43 (70.5) | 1.03 | 0.47–2.27 | 0.93 |
| Oral agentsb | 8 (13.6) | 5 (8.2) | 1.75 | 0.54–5.71 | 0.34 |
| Biological | 4 (6.8) | 3 (4.9) | 1.40 | 0.30–6.57 | 0.66 |
CI, confidence interval; GP, guttate psoriasis; OR, odds ratio; URTI, upper respiratory tract infection; SD, standard deviation; ASLO, antistreptolysin O.